scholarly journals Effects of Mangosteen pericarp Extract to Clinical Improvements, The Plasma Level of IL-6 and Malondialdehyde in Acute Exacerbation of COPD Patients

2018 ◽  
Vol 38 (3) ◽  
pp. 164-172
Author(s):  
Khilyatul Baroroh ◽  
Suradi Suradi ◽  
Ade Rima
Keyword(s):  
Treatment Group ◽  
Plasma Level ◽  
Length Of Stay ◽  
Acute Exacerbation ◽  
Clinical Symptoms ◽  
Control Group ◽  
Chronic Obstructive ◽  
Copd Patients ◽  
Significant Difference ◽  
And Control

Background: Amplification of inflammation in acute exacerbation of chronic obstructive pulmonary disease (COPD) increases inflammatory mediators and oxidative stress in the airways, pulmonary and systemic circulation that are characterized by increased plasma level of IL-6 and MDA, resulting in worsening of clinical symptoms. Xanthones in mangosteen pericarp have anti-inflammatory and antioxidant effects, potentially as an adjuntive therapy in acute exacerbations of COPD. Methods: The aim of this study was to determine the effect of mangosteen pericarp extract to clinical improvements, plasma level of IL-6 and MDA of acute exacerbation COPD patients. A clinical trial of experimental with pretest and posttest was conducted on 34 acute exacerbation of COPD patients in Dr. Moewardi Hospital Surakarta and Dr. Ario Wirawan Lung Hospital Salatiga from April until May 2016. The sample was taken by consecutive sampling. Subjects were divided by randomized double blind technique into the treatment group (n=17) received mangosteen pericarp extract 2x1100mg/day and control group (n = 17) received placebo. Clinical improvements were measured in CAT score and length of stay. CAT score, plasma level of IL-6 and MDA were measured on admission and at discharge. Length of stay based on the number of days of care in hospitals. Results: There was significant difference (p=0,011) towards decreased of IL-6 plasma level between treatment group (-2,17 ± 3,46 pg/ mL) and control group (+1,67 ± 6,81 pg/mL). There were no significant difference towards decreased of length of stay (p=0,34) between treatment group (4,12 ± 1,54 days) and control group (5,24 ± 2,49 days), towards decreased of CAT score (p=0,252) between treatment group (-19,18 ± 3,96) and control group (-18,24 ± 2,75), and towards decreased of MDA plasma level (p=0,986) between treatment group (+0,03 ± 0,36μmol/L) and control group (+0,35 ± 1,58). Conclusions: The addition of mangosteen pericarp extract 2x1100mg/day during hospitalization was significantly lowered plasma levels of IL-6, but were not significant in lowering the CAT score, shortening the length of stay, and reducing the increase in plasma level of MDA.

scholarly journals The Effect of Curcumin On Plasma Histamine Level, PEF Variation and Length of Stay of Patients With Acute Exacerbation Asthma

2018 ◽  
Vol 38 (2) ◽  
pp. 100-108
Author(s):  
Lydia Arista Sutedjo ◽  
Suradi Suradi ◽  
Ana Rima Setijadi
Keyword(s):  
Treatment Group ◽  
Length Of Stay ◽  
Acute Exacerbation ◽  
Inflammatory Marker ◽  
Histamine Level ◽  
Control Group ◽  
Plasma Histamine ◽  
Significant Difference ◽  
Plasma Histamine Level ◽  
And Control

Introduction: Inflammation in asthma occured in airway especially in submucous layer, and involve eosinophil, neutrophil, lymphocytes T, epitheliat cel, basophil, mast cell, and lymphocytes B. Inflammatory cells produce inflammatory mediators (histamine, leucotrienes, and prostanoid), cytokines, and chemokines that can cause bronchocontriction. This study was conducted to determine and prove the effect of curcumin as adjunctive therapy in acute exacerbation asthma. Curcumin is expected to increase the quality therapy of acute exacerbation asthma. The effect of curcumin is known wiith evaluate plasma histamine level, PEF variation, and length of stay of patient with acute exacerbation asthma. Methods: This study is a quasi experimental study with pretest and posttest design. Sampel of study is 30 patients hospitalizes acute exacerbation asthma in Moewardi hospital and Sohadi Prijonegoro Sragen hospital in August 2016 until september 2016. The subject was taken with concecutive random sampling. Independent variable is curcumin 4x550 mg and dependent variables are plasma histamin level, PEF variation, and length of stay. Result: There is no significant difference (P=0.462) of decreasing plasma histamine level between treatment group 3,988±2,739 ng/ml and control group 3,376±1,606 ng/ml. There is no significant difference (P=0.501) of PEF variation between treatment group 28,126±7,886% and control group 30,400±10,217%. There is no significant difference (P=0.936) of length of stay between treatment group perlakuan 6,333±2,193 days and control group 6,400±2,292 days. Conclusion: Giving curcumin in acute exacerbation asthma while hospitalized didn’t reduce inflammatory marker plasma histamin, PEF variation, and length of stay. (J Respir Indo 2018; 38(2): 100-8)

scholarly journals Effects of Omega-3 Polyunsaturated Fatty Acids to The Serum Level of Interleukin-8, Percentage of Forced Expiratory Volume in 1 Second (%FEV1), and COPD Assesment Test Scores in Stable COPD Patients

2017 ◽  
Vol 37 (4) ◽  
pp. 265-277
Author(s):  
Nisfi Angriani ◽  
Suradi Suradi ◽  
Yusup Subagio
Keyword(s):  
Fatty Acids ◽  
Treatment Group ◽  
Polyunsaturated Fatty Acids ◽  
Clinical Symptoms ◽  
Smoke Inhalation ◽  
Control Group ◽  
Omega 3 ◽  
Copd Patients ◽  
Significant Difference ◽  
And Control

Backgorund: Cigarette smoke inhalation and the other exposure can cause of airway inflammatory and it was the most cause of chronic obstruction pulmonary desease (COPD) pathogenesis. The airway inflammatory will release cytokines proinflammation, one of them was interleukin (IL)-8. Omega-3 polyunsaturated fatty acids (PUFA) have anti-inflammatory effect and its can decrease cytokines production in COPD pathogenesis. Methods: This study aimed to analyze effects of omega 3 PUFAs on serum IL-8, %FEV1, and CAT score in stable COPD patients. Clinical trials of experimental with pretest and posttest designs were conducted of 32 stable COPD patients came to clinic in Dr. Moewardi Hospital Surakarta from December 2016 until February 2017. Samples were taken by consecutive sampling. Subjects were divided into two groups include the treatment group (n=16) received standard COPD therapy omega 3 PUFA 600mg/day and the control group (n=16) received only standard COPD therapy for 28 days. Results: There were significant difference (P=0.0001) towards decreased of serum IL-8 between treatment group (-3.56+5.32pg/ml) and control group (8.90+9.98pg/ml), increase difference were no significantly of %VEP1 value (P=0.473) between treatment group (7.02+7.17pg/ml) and control group (5.32+5.97pg/ml), decrease difference of CAT scores significantly (P=0.0001) between treatment group (-16.13+3.03pg/ml) and control group (-4.75+4.17pg/ml). Conclusions: Omega-3 PUFA may decrease airway inflammation with decrease serum IL-8 level significantly, increase of %FEV1 no significantly and improve the clinical symptoms of stable COPD by decreased CAT scores significantly in stable COPD patients. (J Respir Indo. 2017; 37(4): 265-77)

scholarly journals Treatment of Non-erosive Effect of Clinical Study of Gastroesophageal Reflux Disease

2018 ◽  
Vol 6 (3) ◽  
Author(s):  
Qian Liu
Keyword(s):  
Treatment Group ◽  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Reflux Disease ◽  
Clinical Symptoms ◽  
Effective Rate ◽  
Control Group ◽  
Significant Difference ◽  
Before And After ◽  
And Control

<p class="18">Abstract: Objective: To observe the clinical effect of “Chaihu Shugan Powder Zuojin Pill” in the treatment of non-erosive gastroesophageal reflux disease. Methods: Sixty patients with non-erosive gastroesophageal reflux disease were randomly divided into treatment group and control group (30 cases in each group). The patients were treated with “Zaohu Shugan Powder” and “Zangjin Pills” and omeprazole respectively. For 8 weeks, the clinical efficacy and changes in clinical symptoms were observed. Results: The total effective rate was 93.3% in the treatment group and 80.0% in the control group. There was significant difference between the two groups before and after treatment (P &lt;0.05). Conclusion: “Chaihu Shugan Powder Zuojin Pill” can effectively improve the clinical symptoms of non-erosive gastroesophageal reflux disease.</p>

scholarly journals Effects of Green Tea to Absolute Neutrophil Count, MMP-9, %VEP1, and COPD Assessment Test Scores Stable COPD Patients

2020 ◽  
Vol 38 (1) ◽  
pp. 7-15
Author(s):  
Hendrastutik Apriningsih ◽  
Suradi Suradi ◽  
Yusup Subagio Sutanto
Keyword(s):  
Treatment Group ◽  
Green Tea ◽  
Absolute Neutrophil Count ◽  
Neutrophil Count ◽  
Standard Therapy ◽  
Nuclear Factor Κb ◽  
Control Group ◽  
Chronic Obstructive ◽  
Copd Patients ◽  
Significant Difference

Backgrounds: Chronic obstructive pulmonary disease is the leading cause morbidity and mortality worldwide. Cigarette smoke and noxious agent causing oxidative stress activated nuclear factor-κB then increase inflammatory genes releases. Epigallocatechin-3-gallate green tea have antiiinflammatory effect which can be use as addition therapy for stable COPD. Methods: This study aimed to analyze the effect of EGCG to absolute neutrophil count (ANC), serum MMP-9, %FEV1, and CAT score stable COPD patients. Clinical trials of experimental with pre-test and post-test design was conducted on 30 patients in Dr. Moewardi Hospital Surakarta from February-April 2017. Samples were taken by consecutive sampling divided into treatment group (n=15) received standard therapy and green tea capsule 2x500mg/day during 28 days and control group received only standard therapy (n=15). Decreased inflammation measured by ANC and serum MMP-9, improvement of obstruction measured by %FEV1, and clinic improvement measured by CAT score. Results: There were no significant differences (P=0.135) decrease ANC treatment group (-662.45±1446.80 µL) compared control (413.79±2292.90 µL), decrease serum MMP-9 (P=0.413) treatment group (-324.34±333.56 ng/ml) compared control (-181.21±577.52 ng/ml), %FEV1 (P=0.236) treatment group (2.56±10.77), compared control (-4.30±19.12), and significant difference (P=0.034) CAT score treatment group (-1.07±1.16) compared control (-0.20±1.08). Conclusions: The addition of green tea capsule 2x500 mg/day during 28 days was significantly lowered CAT score, decreasing ANC, serum MMP-9 and increasing %FEV1 but not significant. (J Respir Indo 2018; 38(1): 7-15)

scholarly journals Effect of Inhaled Magnesium Sulphate on Bronchodilating Response, Levels of Substance P and Clinical Improvement of Acute Exacerbations COPD Patients

2018 ◽  
Vol 38 (1) ◽  
pp. 16-23
Author(s):  
Prima Karita Sari ◽  
Suradi Suradi ◽  
Jatu Aphridasari
Keyword(s):  
Treatment Group ◽  
Substance P ◽  
Emergency Room ◽  
Acute Exacerbation ◽  
Magnesium Sulphate ◽  
Control Group ◽  
Acute Exacerbation Of Copd ◽  
Copd Patients ◽  
Significant Difference ◽  
Exacerbation Of Copd

Background: Inhaled magnesium sulphate has a bronchodilator and antiinflammatory effect by block the calcium channels and inhibiting substance P. This study aimed to analyze the effect of magnesium sulfate inhalation on bronchodilator response, substance P levels, and clinical improvement on AECOPD patients. Methods: A quasi-experimental clinical trial, pre-test and post-test design with 34 acute exacerbation of COPD patients who are hospitalized in emergency room on Dr. Moewardi Hospital, Surakarta and Ario Wirawan Hospital, Salatiga on March-April 2017 used consecutive sampling. The independent variable is inhaled magnesium sulphate dose of 150 mg 3 times every 20 minutes when the patients was admitted in emergency room, while the dependent variables are peak expiratory flow rate, the plasma levels of substance P and CAT score acute exacerbation of COPD patients. Results: There was a significant difference (P=0.009) decrease of PEFR value of treatment group (111.76±12.37) compared to control group (141.18±24.21). There was a significant difference (P=0.0001) decrease in CAT score of treatment group (-14.88±1.75) compared to control group (-9.00±1.17). There was a significant difference (P=0.0001) treatment group (-1305.92±417.91) than control group (-355.95±206.25). Conclucions: The addition of MgSO4 inhalation of 150 mg during exacerbation increased PEFR, decreased the level of P substance, and decreased the CAT score with statistically significant results. (J Respir Indo 2018; 38(1): 16-23)

scholarly journals Effects of Ginseng Extract to The Plasma Level of Interleukin-8, COPD Assessment Test Scores, and Length of Hospitalization Acute Exacerbation of COPD Patients

2019 ◽  
Vol 38 (4) ◽  
pp. 192-8
Author(s):  
Aslani Threestiana Sari ◽  
Suradi Suradi ◽  
Jatu Aphridasari
Keyword(s):  
Treatment Group ◽  
Plasma Level ◽  
Length Of Stay ◽  
Plasma Levels ◽  
Standard Therapy ◽  
Control Group ◽  
Ginseng Extract ◽  
Copd Exacerbations ◽  
And Control ◽  
Length Of Hospitalization

Background: COPD exacerbations is an acute condition with worsening symptoms and require more intensive treatment changes. Increased inflammatory exacerbations marked increase in plasma levels of IL-8, exacerbation of clinical symptoms and risk of hospitalization. Ginseng extracts have anti inflammatory so it can be used as an additional drug in COPD exacerbations. Method: This study aimed to analyze the effect of ginseng extract on plasma levels of IL-8, CAT scores, and length of hospitalization of patients with COPD exacerbations. Clinical trials of experimental with pre test and post test design was conducted on 34 patients with COPD exacerbation in Dr. Moewardi Hospital Surakarta and Dr. Ario Wirawan Lung Hospital Salatiga from August until September 2016. Samples were taken by consecutive sampling were divided into two groups. The treatment group (n = 17) received standard therapy and ginseng extracts 2x100mg/day and the control group received only standard therapy (n = 17). Clinical improvement measured in CAT score and length of stay. Plasma levels of IL-8, CAT scores, and longer hospitalization time measured at entry and discharge criteria are met. Length of stay based on the number of days of care in hospitals. Results: There were significant difference (p=0.000) towards decreased of of IL-8 plasma level between treatment group (-12.38 ± 10,35pg/ml) and control group (0.65 ± 7,92pg/ml), towards decrease of CAT score (p=0.000) between treatment group (-16.53 ± 1.28) and control group (-12.59 ± 2.87), and length of stay (p = 0.004) between treatment group (4.29 ± 1.45) and control group (5.76 ± 1.20). Conclusions: The addition of ginseng extract 2x100 mg/day during hospitalization was significantly lowered plasma levels of IL-8, CAT scores, and shortening the length of stay. (J Respir Indo. 2018; 38: 192-8)

scholarly journals Effects of a Rehabilitation Programme Using a Nasal Inspiratory Restriction Device in COPD

2021 ◽  
Vol 18 (8) ◽  
pp. 4207
Author(s):  
Jose L. Gonzalez-Montesinos ◽  
Jorge R. Fernandez-Santos ◽  
Carmen Vaz-Pardal ◽  
Jesus G. Ponce-Gonzalez ◽  
Alberto Marin-Galindo ◽  
...  
Keyword(s):  
Pulmonary Rehabilitation ◽  
Rehabilitation Programme ◽  
Group Differences ◽  
Control Group ◽  
Chronic Obstructive ◽  
Maximum Value ◽  
Copd Patients ◽  
Significant Difference ◽  
Pulmonary Rehabilitation Programme ◽  
Positive Increment

Chronic obstructive pulmonary disease (COPD) patients are characterised for presenting dyspnea, which reduces their physical capacity and tolerance to physical exercise. The aim of this study was to analyse the effects of adding a Feel-Breathe (FB) device for inspiratory muscle training (IMT) to an 8-week pulmonary rehabilitation programme. Twenty patients were randomised into three groups: breathing with FB (FBG), oronasal breathing without FB (ONBG) and control group (CG). FBG and ONBG carried out the same training programme with resistance, strength and respiratory exercises for 8 weeks. CG did not perform any pulmonary rehabilitation programme. Regarding intra group differences in the value obtained in the post-training test at the time when the maximum value in the pre-training test was obtained (PostPRE), FBG obtained lower values in oxygen consumption (VO2, mean = −435.6 mL/min, Bayes Factor (BF10) > 100), minute ventilation (VE, −8.5 L/min, BF10 = 25), respiratory rate (RR, −3.3 breaths/min, BF10 = 2), heart rate (HR, −13.7 beats/min, BF10 > 100) and carbon dioxide production (VCO2, −183.0 L/min, BF10 = 50), and a greater value in expiratory time (Tex, 0.22 s, BF10 = 12.5). At the maximum value recorded in the post-training test (PostFINAL), FBG showed higher values in the total time of the test (Tt, 4.3 min, BF10 = 50) and respiratory exchange rate (RER, 0.05, BF10 = 1.3). Regarding inter group differences at PrePOST, FBG obtained a greater negative increment than ONBG in the ventilatory equivalent of CO2 (EqCO2, −3.8 L/min, BF10 = 1.1) and compared to CG in VE (−8.3 L/min, BF10 = 3.6), VCO2 (−215.9 L/min, BF10 = 3.0), EqCO2 (−3.7 L/min, BF10 = 1.1) and HR (−12.9 beats/min, BF10 = 3.4). FBG also showed a greater PrePOST positive increment in Tex (0.21 s, BF10 = 1.4) with respect to CG. At PreFINAL, FBG presented a greater positive increment compared to CG in Tt (4.4 min, BF10 = 3.2) and negative in VE/VCO2 intercept (−4.7, BF10 = 1.1). The use of FB added to a pulmonary rehabilitation programme in COPD patients could improve tolerance in the incremental exercise test and energy efficiency. However, there is only a statically significant difference between FBG and ONBG in EqCO2. Therefore, more studies are necessary to reach a definitive conclusion about including FB in a pulmonary rehabilitation programme.

RISK PREDICTION FOR ARRHYTHMIA IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

2021 ◽  
Vol 74 (10) ◽  
pp. 2605-2609
Author(s):  
Tetyana M. Ternushchak ◽  
Marianna I. Tovt-Korshynska
Keyword(s):  
P Wave ◽  
Doppler Imaging ◽  
Control Group ◽  
Chronic Obstructive ◽  
Conduction Time ◽  
Electromechanical Delay ◽  
P Wave Dispersion ◽  
Atrial Electromechanical Delay ◽  
Copd Patients ◽  
Significant Difference

The aim: To evaluate P-wave dispersion (PwD), as an independent predictor of atrial fibrillation, corrected QT interval dispersion (cQTD), the noninvasive marker of ventricular arrhythmia and sudden cardiac death, investigate the atrial electromechanical delay in patients with COPD and assess their relation with the severity of the disease. Materials and methods: We prospectively enrolled consecutive patients with newly diagnosed COPD (n = 53, age 41.2 ± 6.8 years), compared with an age-matched healthy control group (n = 51, age 40.9 ± 6.5 years). A standard 12-lead electrocardiogram of each patient was analyzed for PwD and сQTD. Atrial electromechanical delay was analyzed by echocardiographic tissue Doppler imaging. The difference between PAs-PAl, PAs-PAt, and PAl-PAt were defined as left intra-atrial, right intra-atrial, and interatrial electromechanical delays (EMD), respectively. Results: PwD was higher in COPD patients than in control subjects (39.47 ± 3.12 ms vs. 30.29 ± 3.17 ms, p < 0.05). In comparison between control group and COPD subgroups (mild, moderate and severe), there was a statistically significant difference among these free groups in terms of PwD. Subgroup analyses showed that this difference was mainly due to patients with severe COPD. Regarding cQTD, there was a statistically significant increase in COPD patients 57.92 ± 3.43 ms vs 41.03 ± 5.21 ms, p < 0.05 respectively. PAs, PAl and PAt durations, right intra-atrial and interatrial EMD were also significantly longer in COPD patients (p < 0.05). Furthermore, there were significant negative correlations between FEV1 and PwD (r = – 0.46, p < 0.05), right intra-atrial (r = – 0.39 ms, p < 0.05), interatrial EMD ( r = – 0.35 ms, p < 0.05) and cQTD (r = – 0.32, p < 0.05). Conclusions: Atrial conduction time, such as inter- and intra-atrial EMD intervals, PwD and cQTD were longer than in healthy controls and correlated with the severity of COPD. These parameters offer a non-invasive and cost-effective assessment method for detecting patients at high risk of arrhythmia. Nevertheless, further prospective investigations on this issue are required.

The Effect of Telerehabilitation on Quality of Life, Exercise Capacity, and Spirometry Indexes in Patients with Chronic Obstructive Pulmonary Disease in Masih Daneshvari Hospital

2021 ◽  
Author(s):  
Somayeh Ghadimi ◽  
Atefeh Fakharian ◽  
Mohsen Abedi ◽  
Reyhaneh Zahiri ◽  
Mahsan Norouz Afjeh ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Control Group ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Copd Patients ◽  
And Control

Background: Chronic Obstructive Pulmonary Disease (COPD) leads to limited activity and reduced quality of life. Treatment of this disease is a long-term process that requires the cooperation of patients in monitoring and treatment. Methods: In the present study which was conducted from April 2019 to March 2021 in Masih Daneshvari Hospital, Tehran, Iran, 75 patients were randomly divided into telerehabilitation and control groups. Patients in the control group received pulmonary rehabilitation including respiratory, isometric, and aerobic exercises for 8 weeks, three times per week. In the second group, patients were given a lung rehabilitation booklet and asked to repeat the exercises three times a week for four weeks according to a specific schedule. In addition, patients installed Behzee care application on the mobile phone that recorded various indicators such as heart rate, SpO2, dyspnea, fatigue, and daily activities. This application reminded the patient of the program every day and at a specific time. Finally, the patients’ conditions were compared in the two groups after 8 weeks using CAT and mMRC questionnaires and 6-Minute Walk (6MW) exercise indices as well as spirometry tests. Results: In all four indicators (6MW, CAT,  and mMRC questionnaires as well as spirometry), patients showed improvement after rehabilitation (p<0.001). This improvement was significantly higher in the telemedicine group compared to the other group (p<0.01). Conclusion: The use of telerehabilitation in COPD patients is effective in improving spirometry indices, quality of life, as well as activity and sports indices.

scholarly journals The Effects of Quercetinon Interleuikin (IL-8) Serum, %Forced Expiratory Volume in One Second (FEV1), and COPD Assessment Test (CAT) Scores in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients

2019 ◽  
Vol 39 (2) ◽  
pp. 103-112
Author(s):  
Maratus Sholihah ◽  
Suradi Suradi ◽  
Jatu Aphridasari
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Treatment Group ◽  
Serum Level ◽  
Pulmonary Disease ◽  
Standard Therapy ◽  
Flavonoid Compound ◽  
Control Group ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Copd Patients

Introduction: Chronic obstructive pulmonary disease (COPD) is the leading cause of morbidity and mortality worldwide. Cigarette smoke and noxious agent result in oxidative stress and activate release of inflammatory mediators such as Interleukin-8 (IL-8). Quercetin is a flavonoid compound containing anti-inflammatory effects which can be used as an adjuvant therapy in stable COPD. Objective: To analyze the effect of quercetin on serum IL-8 levels, % VEP1, and CAT score of stable COPD patients. Methods: Experimental clinical trial with pre-test and pasca-test design was performed in 30 patients with stable COPD in Dr. Moewardi Surakarta between December 2017 and January 2018. The samples taken by using purposive sampling were divided into two groups treatment groups received standard therapy and quercetin 500mg/day for 28 days and control groups only received standard therapy. The decrease in inflammation was measured by serum IL-8 examination, improvement of obstruction measured by %FEV1 and clinical improvement measured by CAT score. Results: IL-8 serum level was significantly lower in treatment group than of in control group (p=0,001). The percentage of FEV1 was insignificant different between the two group (p=0,236). However CAT score was significantly lower in treatment group compared to that of in control group (p=0,001) Conclusions: Quercetin can decrease IL-8 serum level and decrease CAT score when given in combination with standard therapy for COPD patients. (J Respir Indo 2019; 39(2))

Sign in / Sign up

Export Citation Format

Share Document